DARPA is determined to develop brain-machine interface technology capable of safely and reliably recording enough information from neurons to control “high-performance prosthetic limbs” that will help amputees or people with paralysis regain lost movement. A new implantable device invented by researchers at the University of Melbourne in Australia could be a big step in that direction.
MindMaze has a long-term plan to transform medical care using imaging techniques such as virtual reality and augmented reality, and now it has $100 million from investors to explore those possibilities. The startup, based in Lausanne, Switzerland, is making San Francisco its U.S. headquarters, drawn here by the Bay Area’s active virtual reality community and its top research universities. And after its first funding round, announced today, MindMaze has its eye on acquisitions, company founder and CEO Tej Tadi says.
Synlogic just inked its first partnership, with AbbVie, last week. Today the Cambridge, MA-based startup got the cash needed to get to another first: Tests of its genetically altered microbes in human patients.
Synlogic has raised a $40 million Series B round led by new investor Orbimed HealthCare Fund Management. The company, founded in 2014 by Atlas Venture and New Enterprise Associates—which also participated in the round—has now raised about $70 million since inception.
The hospital – at least the intensive care section of it – is a dangerous place. As many as 30% of the people who go in do not come out, and half of those that do emerge with a slew of problems that require additional treatment – high blood pressure, ambulatory issues, digestive problems, and more, often requiring extensive and expensive time in rehab.
Intensive care patients are especially vulnerable to problems such as kidney and liver failure, cardiac arrest, shock, organ failure, and — perhaps the greatest danger of all — sepsis, which is one of the leading causes of death of ICU patients, both while they are in the hospital and when they get out.
Yumanity Therapeutics has reeled in a $45 million Series A round as it uses nontraditional ways to find drugs that might treat neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
The Cambridge, MA-based startup is based upon a drug discovery system created by its cofounder Sue Lindquist, a member and former director of the Whitehead Institute for Biomedical Research, which is affiliated with MIT. Lindquist and her cofounder Tony Coles, the former CEO of Onyx Pharmaceuticals, helped bootstrap Yumanity for some time, as my colleague Ben Fidler reported last year. (Both are pictured above.)
Beste urte batez, Bexen Cardio eta Bexen Medical Arab Health-en izan dira, iragan urtarrilean Dubaien ospatu den osasun-sektoreko azoka esanguratsuan, hain zuzen.
Azken urteotan gora egin du Arab Health azokak. 4.000 erakustoki baino gehiago eta 130.000 parte-hartzailetik gora elkartu dira urtarrilaren 25tik 28ra bitartean izan den azokaren aurtengo edizioan, Dubaien.
The brain is relatively uncharted territory for tech. Harvard University geneticist George Church has written about impending technologies that “extend our brain both biologically and electronically,” while AFP describes the brain as “the next frontier for the tech sector.”
Lantern, a mental health startup that offers tools to deal with stress, anxiety and body image has raised a $17 million Series A round led by the University of Pittsburgh Medical Center’s venture arm with participation from previous investors such as Mayfield and SoftTechVC.
Una enfermera sumergió un vendaje en un líquido incoloro que contenía virus de una cloaca tóxica de París, un pozo de Malí y un río sucio de India. Luego, lo aplicó suavemente sobre la espalda severamente quemada de una mujer mayor.
“Está sanando”, dijo Ronan Le Floch, el doctor que supervisaba el cuidado de la mujer. El matiz verdoso de la dolorosa herida, una señal de una posible infección bacteriana mortal, había desaparecido.
El tratamiento líquido era un cóctel de unos 1.000 millones virus llamados bacteriófagos, o fagos, que tienen la capacidad de matar bacterias. Los fagos son poco conocidos por los doctores de Occidente, pero han formado parte del arsenal antibacteriano de los países de la ex Unión Soviética desde hace décadas.
